Adel Moussa
66Patents
13h-index
70Co-inventors
87Inventor score
Filing activity: Mar 19, 1997 → Jul 24, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9211300B2 | 4′-fluoro nucleosides for the treatment of HCV | Chemistry; Metallurgy | 55 | Active |
| US9109001B2 | 3′,5′-cyclic phosphoramidate prodrugs for HCV infection | Chemistry; Metallurgy | 44 | Active |
| US7598373B2 | Process for the production of 2-C-methyl-D-ribonolactone | Emerging Cross-Sectional Technologies | 41 | Expired |
| US9187515B2 | 2′,4′-fluoro nucleosides for the treatment of HCV | Chemistry; Metallurgy | 40 | Active |
| US9192621B2 | Esters and malonates of SATE prodrugs | Chemistry; Metallurgy | 29 | Active |
| US7781576B2 | Process for preparing a synthetic intermediate for preparation of branched nucleosides | Chemistry; Metallurgy | 28 | Active |
| US9339541B2 | Thiophosphate nucleosides for the treatment of HCV | Emerging Cross-Sectional Technologies | 25 | Active |
| US6331564A | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | Chemistry; Metallurgy | 22 | Expired |
| US9828410B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Chemistry; Metallurgy | 18 | Active |
| US9309275B2 | 3′-deoxy nucleosides for the treatment of HCV | Chemistry; Metallurgy | 17 | Active |
| US6028103A | Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation | Chemistry; Metallurgy | 14 | Expired |
| US10519186B2 | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus | Chemistry; Metallurgy | 14 | Active |
| US10005811B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Chemistry; Metallurgy | 13 | Active |
| US10000523B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Chemistry; Metallurgy | 13 | Active |
| US10874687B1 | Highly active compounds against COVID-19 | Chemistry; Metallurgy | 13 | Active |
| US10239911B2 | Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Chemistry; Metallurgy | 12 | Active |
| US8093379B2 | Macrocyclic serine protease inhibitors | Human Necessities | 7 | Active |
| US6462221B1 | Synthesis of nitroalcohol diastereomers | Emerging Cross-Sectional Technologies | 5 | Expired |
| US10815266B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Chemistry; Metallurgy | 4 | Active |
| US6752929B1 | Methods of separating FTC isomers and derivatives thereof | Emerging Cross-Sectional Technologies | 4 | Expired |
| US10875885B2 | β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment | Chemistry; Metallurgy | 3 | Active |
| US10946033B2 | 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment | Emerging Cross-Sectional Technologies | 3 | Active |
| US10870672B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Chemistry; Metallurgy | 3 | Active |
| US10870673B2 | β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Chemistry; Metallurgy | 3 | Active |
| US10906928B2 | Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus | Chemistry; Metallurgy | 2 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.